Highlighted Research Articles

A major goal of early cancer detection is to identify subclinical disease when the tumor burden is low such that treatments are more effective, but exactly how early cancers can be detected prior to clinical signs or symptoms remains unknown. By analyzing prospectively collected serial plasma samples from the Atherosclerosis Risk in Communities (ARIC) study, Wang and colleagues demonstrated that circulating tumor DNA (ctDNA) can be detected more than 3 years prior to cancer diagnosis in some patients. This study provides the benchmark sensitivities required for ctDNA-based tests to achieve such very early cancer detection.See article, p. 1794.Global collaboration in medical research is often constrained by strict privacy laws preventing cross-border sharing of sensitive patient data. To overcome this, Cai and colleagues used federated deep learning to train artificial intelligence (AI) models in local servers such that only model insights, but not data, were shared with a central server. Accurate cancer subtyping was achieved using proteomes from over 7,500 cancer samples in 30 cohorts from six countries and by integrating additional proteomic data from diverse mass spectrometry platforms. Notably, results from privacy-restricted data were as accurate as those obtained from centrally-pooled data. This approach supports privacy-compliant, large-scale AI development in biomedical research.See article, p. 1803.Natural killer (NK) cells can have potent anticancer function. However, Pozniak and colleagues revealed that cytotoxic NK cells accumulate at the tumor rim in non-responding melanoma lesions following immune checkpoint blockade (ICB). In a mouse model with an immune-excluded phenotype, depleting NK cells or inhibiting CX3CR1, which prevents NK cell recruitment at the tumor rim, allowed increased T-cell infiltration and tumor eradication. These findings highlight an unexpected role for NK cells in contributing to ICB resistance and identify new therapeutic strategies for treating immune-excluded tumors.See article, p. 1819.NK cells have long been considered beneficial for antitumor immunity, but Song and colleagues revealed a distinct immunosuppressive role for tumor-associated NK cells. NK cells were found to limit CD8+ T-cell responses by competing for critical cytokines and suppressing effector differentiation through CD8+ T cell–intrinsic RARα signaling. Depleting NK cells led to the emergence of highly functional CD8+ T cells and improved tumor control during PD-(L)1 blockade. Importantly, analysis of patient datasets showed that elevated NK cell signatures are associated with poor immunotherapy responses, underscoring the clinical relevance of targeting suppressive NK cells to improve outcomes.See article, p. 1835.Biliary tract cancers (BTC) are aggressive and molecularly heterogeneous tumors. Vijay and colleagues present a comprehensive atlas of 63 BTC cell lines generated through multiomic profiling and genome-scale CRISPR screening. The study identified biologically distinct subtypes defined by differentiation programs and genotype, each with unique dependencies and potential therapeutic targets. Shared and subtype-specific vulnerabilities—including EGFR, integrin-α3, the detoxification enzyme UXS1, and the lineage-specifying transcription factors GRHL2, TP63, and HNF1B—may inform precision oncology strategies. This atlas thus serves as a resource for understanding BTC heterogeneity and guiding subtype-specific therapeutic development.See article, p. 1858.Histone deacetylase inhibitors (HDACi) combined with PD-1 blockade show promise in hematologic malignancies but have limited efficacy in solid tumors. Wang and colleagues demonstrated that, while HDACi augmented CD8+ T-cell cytotoxicity, it concurrently induced abnormal angiogenesis that restricted T-cell infiltration. This challenge was addressed by the introduction of a triple therapy regimen—HDACi, anti-angiogenic treatment, and PD-1 blockade (CAP)—which normalized tumor vasculature, converted immune-cold tumors into immune-inflamed tumors, and overcame resistance to immunotherapy. These findings offer a rational strategy to improve the efficacy of immunotherapy in solid tumors.See article, p. 1883.In studying a cohort of patients treated with CAR T-cell therapy, Marcos-Kovandzic and colleagues found that a specific gut microbiota signature was associated with CAR T-cell potency. Most notably, Akkermansia spp. were enriched in responder patients. Administration of Akkermansia spp. to mice bearing B cell lymphomas led to the enhancement of the antitumor effects of CAR T-cell infusion. The improvement in CAR T-cell efficacy was associated with early trafficking of cytotoxic CAR T-cells to the tumor-free bone marrow. The aryl hydrocarbon receptor (AHR) was required for the beneficial effect of this bacterial supplementation.See article, p. 1905.Fusion genes are frequently cancer drivers, but the molecular mechanisms underlying their formation remain unclear. Khan and colleagues identified HPV integration as the instigator of genomic rearrangements that led to the formation of FGFR3–TACC3 and other fusion genes in oropharyngeal cancers. FGFR3–TACC3 expression decreased the ubiquitination and degradation of viral E6 and E7 oncoproteins, furthering the oncogenesis of HPV. Coexpression of HPV16 E6/E7 and FGFR3–TACC3, but neither alone, was sufficient for tumor development in both xenograft and syngeneic mouse models. Therefore, this study provides evidence that expression of HPV16 oncoproteins and the subsequent host gene fusions generated from HPV integration sites can be sufficient for cancer development.See article, p. 1927.Lymph nodes (LN) are the most common site of solid tumor metastasis, yet they are also the staging grounds for antitumor immunity. In this study, Kahn and colleagues sought to understand what makes LNs so highly susceptible to metastasis despite their pivotal immune roles. The authors found that regulatory T cells within the LN outcompete tumor-specific CD8+ T cells for IL2, therefore preventing the latter from acquiring cytolytic activity. LNs thus possess an intrinsic mechanism to prevent CD8+ T cells from killing their targets, with broad implications for immunology and immunotherapy.See article, p. 1949.